Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Award
- £7.7m to £8.6m
- Closes
- 17 February 2027
- Funder
- European Commission (Horizon Europe)
Who can apply for Development of monoclonal antibodies to prevent and treat infections from Flaviviruses?
Development of monoclonal antibodies to prevent and treat infections from Flaviviruses is a funding programme from European Commission (Horizon Europe), offering £7.7m to £8.6m and closing on 17 February 2027. Below are the eligibility rules EchoGrant read from the funder's own page, grouped by what they cover. They are quoted from the funder, so treat the official page as the final word.
Who can apply
- The participation of tart-up , micro, mall and medium- ized enterpri e (SME ) i encouraged with the aim of trengthening their cientific and technological foundation , enhancing their innovation potential, and exploring po ibilitie for commercial exploitation.
Where you need to be based
- Location: UK. The UK i a ociated to Horizon Europe, o UK organi ation can apply on the ame term a EU one unle the condition below ay otherwi e.
Sector or focus
- Thi topic contribute to trengthening the Re earch and Innovation eco y tem within the EU and upport the implementation of the European Medical Countermea ure Strategy.
What the funding is for
- Applicant hould explicitly tate in their propo al which of the following Flaviviru e i targeted and the propo ed work hould addre only thi pecific Flaviviru .
- Propo al hould focu on antibodie produced or derived from a ingle cell clone through recombinant expre ion, uch a B-cell derived antibodie , hybridoma derived antibodie and nanobodie .
- A propo al under thi topic are expected to include clinical tudie , the u e of the template i trongly encouraged.
Do you meet these rules?
EchoGrant checks your organisation against every rule above and tells you which ones you pass, which you fail and which need an answer from you.
Common questions
Who can apply for Development of monoclonal antibodies to prevent and treat infections from Flaviviruses?
The participation of tart-up , micro, mall and medium- ized enterpri e (SME ) i encouraged with the aim of trengthening their cientific and technological foundation , enhancing their innovation potential, and exploring po ibilitie for commercial exploitation. This is the funder’s own wording; check the official page before you apply.
How much is the Development of monoclonal antibodies to prevent and treat infections from Flaviviruses award?
The funder’s page gives the award as £7.7m to £8.6m. Check the official page for how it is paid and any match funding.
When is the Development of monoclonal antibodies to prevent and treat infections from Flaviviruses deadline?
The deadline we have recorded is 17 February 2027. Funders sometimes move dates, so confirm on the official page.
Information is taken from the funder's public page and may be out of date. EchoGrant is not the funder and does not guarantee eligibility or funding. Always confirm details with the funder before applying.